用于治疗慢性肾脏病的合生元的临床评估：系统评价与荟萃分析方案
Clinical assessment of synbiotics for treating chronic kidney disease: A protocol for systematic review and meta-analysis.
作者信息
Li Xiao-Jun, Lu Yan-Yan, Wang Yuan
机构信息
Department of Nephrology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China.
出版信息
Medicine (Baltimore). 2020 Dec 4;99(49):e22993. doi: 10.1097/MD.0000000000022993.
BACKGROUND
This research aims to evaluate the efficacy and safety of synbiotics for treating chronic kidney disease.
METHODS
Related articles written in English were sourced from EMBASE, PubMed, Cochrane Library, and China National Knowledge Infrastructure. These articles were used in the evaluation of the effect of synbiotics for treating chronic kidney disease. The extent of the relationship was assessed by calculating the pooled risk ratio, mean differences or standardized mean difference along with the equivalent 95% confidence intervals. The risk of bias introduced through each study was considered by adopting the Cochrane Risk of Bias Tool. Suitable statistical research methods were utilized for the synthesis of the data. The RevMan 5.3 software was used to conduct all statistical analysis.
RESULTS
The final results of the current study is due to be included in a peer-reviewed journal.
CONCLUSION
The final remarks of the current study will be useful evidence for determining whether synbiotics is an effective and safe therapeutic method for treating chronic kidney disease.
OSF REGISTRATION NUMBER
DOI 10.17605/OSF.IO/UASF4 (https://osf.io/uasf4/).
背景
本研究旨在评估合生元治疗慢性肾脏病的疗效和安全性。
方法
从EMBASE、PubMed、Cochrane图书馆和中国知网获取英文相关文章。这些文章用于评估合生元治疗慢性肾脏病的效果。通过计算合并风险比、平均差或标准化平均差以及等效的95%置信区间来评估关联程度。采用Cochrane偏倚风险工具考虑每项研究引入的偏倚风险。使用合适的统计研究方法进行数据合成。使用RevMan 5.3软件进行所有统计分析。
结果
本研究的最终结果将发表在同行评审期刊上。
结论
本研究的最终结论将为确定合生元是否是治疗慢性肾脏病的有效且安全的治疗方法提供有用证据。
开放科学框架注册号
DOI 10.17605/OSF.IO/UASF4 (https://osf.io/uasf4/)。
Zotero 插件